Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Change in Inventory: 2012-2025

Historic Change in Inventory for Ani Pharmaceuticals (ANIP) over the last 13 years, with Sep 2025 value amounting to $8.2 million.

  • Ani Pharmaceuticals' Change in Inventory rose 28.30% to $8.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.4 million, marking a year-over-year decrease of 58.88%. This contributed to the annual value of $21.3 million for FY2024, which is 264.44% up from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Change in Inventory of $8.2 million as of Q3 2025, which was up 798.68% from $908,000 recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Change in Inventory registered a high of $11.6 million during Q2 2024, and its lowest value of -$6.0 million during Q3 2021.
  • Moreover, its 3-year median value for Change in Inventory was $2.3 million (2023), whereas its average is $3.3 million.
  • Per our database at Business Quant, Ani Pharmaceuticals' Change in Inventory slumped by 437.85% in 2021 and then spiked by 1,635.58% in 2024.
  • Quarterly analysis of 5 years shows Ani Pharmaceuticals' Change in Inventory stood at $5.5 million in 2021, then surged by 70.52% to $9.5 million in 2022, then plummeted by 51.33% to $4.6 million in 2023, then tumbled by 85.34% to $675,000 in 2024, then rose by 28.30% to $8.2 million in 2025.
  • Its Change in Inventory was $8.2 million in Q3 2025, compared to $908,000 in Q2 2025 and $625,000 in Q1 2025.